Paper42732142
What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol.
Martyn E and 14 others. Wellcome Open Res, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol. Papers, record 42732142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42732142
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CC2223 | Wellcome Trust | United Kingdom | PubMed |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38577526 | Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis. | World J Hepatol | 2024 | https://conductscience.org/library/papers/38577526 | PubMed |
| 2 | 30006442 | Ten simple rules for conducting umbrella reviews. | Evid Based Ment Health | 2018 | https://conductscience.org/library/papers/30006442 | PubMed |
| 3 | 38429161 | Current status and future trends of the global burden of MASLD. | Trends Endocrinol Metab | 2024 | https://conductscience.org/library/papers/38429161 | PubMed |
| 4 | 28935701 | AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. | BMJ | 2017 | https://conductscience.org/library/papers/28935701 | PubMed |
| 5 | 36625022 | The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis. | Expert Rev Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/36625022 | PubMed |
| 6 | 24581293 | Systematic review finds overlapping reviews were not mentioned in every other overview. | J Clin Epidemiol | 2014 | https://conductscience.org/library/papers/24581293 | PubMed |
| 7 | 38356666 | Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis. | Exp Ther Med | 2024 | https://conductscience.org/library/papers/38356666 | PubMed |
| 8 | 36727674 | AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. | Hepatology | 2023 | https://conductscience.org/library/papers/36727674 | PubMed |
| 9 | 35192111 | Liver biopsy for assessment of chronic liver diseases: a synopsis. | Clin Exp Med | 2023 | https://conductscience.org/library/papers/35192111 | PubMed |
| 10 | 40227096 | The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis. | Hepatol Commun | 2025 | https://conductscience.org/library/papers/40227096 | PubMed |
| 11 | 31903714 | Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors? | Liver Int | 2020 | https://conductscience.org/library/papers/31903714 | PubMed |
| 12 | 38432237 | Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. | Lancet | 2024 | https://conductscience.org/library/papers/38432237 | PubMed |
| 13 | 25662901 | Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. | Lancet Neurol | 2015 | https://conductscience.org/library/papers/25662901 | PubMed |
| 14 | 37533208 | Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta-analysis. | J Viral Hepat | 2023 | https://conductscience.org/library/papers/37533208 | PubMed |
| 15 | 36111362 | Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis. | Hepatology | 2023 | https://conductscience.org/library/papers/36111362 | PubMed |
| 16 | 39488409 | Steatotic liver disease. | Lancet | 2024 | https://conductscience.org/library/papers/39488409 | PubMed |
| 17 | 40638020 | Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis. | Infect Dis Ther | 2025 | https://conductscience.org/library/papers/40638020 | PubMed |
| 18 | 37157776 | Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. | Clin Mol Hepatol | 2023 | https://conductscience.org/library/papers/37157776 | PubMed |
| 19 | 40707650 | Viral hepatitis: breaking down barriers. | Nat Rev Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/40707650 | PubMed |
| 20 | 37364816 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature. | Ann Hepatol | 2024 | https://conductscience.org/library/papers/37364816 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42732142 | What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol. | Wellcome Open Res | 2026 | https://conductscience.org/library/papers/42732142 |
Source PubMed
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| figshare | 10.6084/m9.figshare.31981305 |
Source figshare
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42732142
GET https://conductscience.org/api/papers/v1/42732142/references?page=2